MedTrace Logo

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

NCT05560009 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2025-07-10

No results posted yet for this study

Summary

This study evaluates the use of a new imaging agent called fluorodopa F 18 (18F-DOPA) with positron emission tomography/magnetic resonance imaging (PET/MRI) for assessing treatment response in patients undergoing standard of care radiation therapy and/or surgery for high-grade soft tissue sarcomas that are new or that have come back (recurrent). Though there have been improvements in treatment options for soft tissue sarcomas, there is currently a need for a non-invasive way to determine a patient's potential benefit from receiving one of these treatments. 18F-DOPA with PET/MRI allows a patient's tumor to be visualized and their response to a given treatment assessed.

Conditions

  • Recurrent Soft Tissue Sarcoma
  • Resectable Soft Tissue Sarcoma
  • Soft Tissue Sarcoma

Interventions

DRUG

Fluorodopa F 18

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/MRI

RADIATION

Radiation Therapy

Receive standard of care radiation therapy

PROCEDURE

Surgical Procedure

Undergo standard of care surgery

Sponsors & Collaborators

Principal Investigators

  • Deanna Hasenauer, Ph.D. · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-10
Primary Completion
2024-07-09
Completion
2024-07-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05560009 on ClinicalTrials.gov